LLY · NYSE · Drug Manufacturers - General

Eli Lilly

Develops cardiometabolic, cancer, immunology, and neuroscience medicines led by tirzepatide.

$1,173.00
After-hours close−0.95 (−0.08%)
At close$1,173.95(−0.18%)

Breakdown13F · Form 4

Institutions 239.17%Insiders 0.13%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 941.74M · Float 848.69M · 90.1% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
Lilly Endowment Inc90.38M9.60%13FJul 23, 2026
BlackRock, Inc.67.54M7.17%13FAug 7, 2026
Vanguard Capital Management LLC53.53M5.68%13FAug 13, 2026
PNC Financial Services Group, Inc.51.32M5.45%13FAug 7, 2026
State Street Corp36.22M3.85%13FAug 7, 2026

Institutions13F, as of Jun 30, 2026

4,772 holders · 2.25B shares · 420 new positions · 2,605 increased · 1,494 reduced · 167 closed

HolderShares% outstandingChg q/qFiled
Lilly Endowment Inc90.38M9.60%−1.52MJul 23, 2026
BlackRock, Inc.67.54M7.17%+1.16MAug 7, 2026
Vanguard Capital Management LLC53.53M5.68%+167.1KAug 13, 2026
PNC Financial Services Group, Inc.51.32M5.45%−6.2KAug 7, 2026
State Street Corp36.22M3.85%+605.8KAug 7, 2026
FMR LLC28.46M3.02%+2.12MAug 13, 2026
Capital Research Global Investors20.87M2.22%−3.76MAug 12, 2026
Vanguard Portfolio Management LLC20.86M2.21%−117.8KAug 13, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Lilly Endowment, Inc.9.70%91.90M13GApr 20, 2026
The PNC Financial Services Group, Inc.5.39%51.15M13GFeb 7, 2025

InsidersForm 4

InsiderRoleShares% outstandingFiled
Lilly Endowment Incother: Former 10% Shareholder91.88M9.76%May 7, 2026
David A. Ricksdirector, officer: President, Chair, and CEO571.7K0.06%Feb 11, 2026
Daniel Skovronskyofficer: EVP, CS&PO & Pres. LRL160.1K0.02%Feb 11, 2026
J. Erik Fyrwalddirector75.4K0.01%Aug 18, 2026
Ralph Alvarezdirector56.5K0.01%Aug 18, 2026
Patrik Jonssonofficer: EVP & President, LLY Int'l54.1K0.01%Aug 18, 2026
Edgardo Hernandezofficer: EVP & Pres., Mfg. Operations46.1K0.00%Feb 11, 2026
Anat Hakimofficer: EVP, GC & Secretary34.9K0.00%Aug 10, 2026
Ilya Yuffaofficer: EVP&Pres, LLY USA&Global Capab29.8K0.00%Jun 11, 2026
Jacob van Naardenofficer: EVP,Pres LLY Oncology&HdCorpBD26.6K0.00%Feb 11, 2026

3 ten-percent owners hold 91.88M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 46 people have not refiled in the last 18 months (2.46M shares), so they are not in the figure above

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Aug 17, 2026
Patrik Jonssonofficer: EVP & President, LLY Int'l
Sale6,500$1,175.1054,147
Aug 10, 2026
Donald A. Zakrowskiofficer: SVP, Finance, & CAO
Sale2,000$1,185.011,526
Aug 7, 2026
Anat Hakimofficer: EVP, GC & Secretary
Sale5,000$1,190.0011,875
Jun 10, 2026
Ilya Yuffaofficer: EVP&Pres, LLY USA&Global Capab
Sale2,500$1,150.7729,804
May 6, 2026
Lilly Endowment Incother: Former 10% Shareholder
Sale · 2 lots15,828$995.3691,881,150
Jan 7, 2026
Lilly Endowment Inc10 percent owner
Sale · 30 lots292,148$1,103.4891,896,978
Jan 5, 2026
Lilly Endowment Inc10 percent owner
Sale1,390$1,085.0192,189,126
Dec 29, 2025
Lilly Endowment Inc10 percent owner
Sale3,593$1,085.0492,190,516
Dec 23, 2025
Lilly Endowment Inc10 percent owner
Sale240$1,085.0492,196,738
Dec 24, 2025
Lilly Endowment Inc10 percent owner
Sale2,629$1,085.1792,194,109

CongressHouse and Senate disclosures

MemberTypeAmountOwnerTradedDisclosed
Sen. John Boozman · ARSale$1,001 – $15,000JointNov 21, 2025Aug 24, 2026
Rep. Michael RulliSale$1,001 – $15,000Jul 1, 2026Aug 10, 2026
Rep. Michael RulliPurchase$1,001 – $15,000Jan 2, 2026Aug 10, 2026
Rep. Michael RulliSale$1,001 – $15,000Dec 2, 2025Aug 10, 2026
Sen. Tommy Tuberville · ALSale$15,001 – $50,000JointApr 15, 2025Aug 5, 2026